Schmahmann, Jeremy D.
Funding for this research was provided by:
NIH (1U01NS104326-01, 1R01NS080816-01A1)
the National Ataxia Foundation
Article History
Received: 29 May 2019
Accepted: 5 June 2019
First Online: 25 June 2019
Compliance with ethical standards
:
: Dr. Schmahmann discloses that he consults for Cadent Therapeutics and is a site principal investigator for Biohaven Pharma. He declares no conflict of interest relevant to the content of this manuscript.